study to assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke

Conditions: Acute Cerebral Ischemia

Summary: this is a prospective, multicenter, randomized, double-blind, parallel, phase iv study designed to evaluate the safety and efficacy of sovateltide (pmz-1620, irl-1620) as a potential treatment for cerebral ischemic stroke.

the presence of stem cells in the brain that become active after brain injury is an interesting aspect of regeneration and repair after stroke. the intravenous administration of sovateltide (tyvalzi™, irl 1620) enhances the activity of neuronal progenitor cells and angiogenesis in the brain. this promotes the formation of new mature neurons and blood vessels, aiding in the repair process. additionally, sovateltide exhibits anti-apoptotic activity, preventing cell death, and it can increase cerebral blood flow when administered after ischemia. these properties make sovateltide a promising candidate for promoting brain repair and facilitating recovery following acute ischemic stroke. the study aims to evaluate the safety and efficacy of sovateltide in 160 patients with acute cerebral ischemic stroke. sovateltide will be administered intravenously in addition to standard treatment. the patients will be divided into two groups, with 80 patients in each. group 1 will receive sovateltide along with standard treatment, while group 2 will receive normal saline along with standard treatment. the study will span approximately 18 months, with a patient enrollment period of around 15 months. each patient will be followed for a total of 3 months, with three study visits during that period. the study will adhere to ethical guidelines and obtain informed consent from patients or their legally acceptable representatives. efficacy analysis will be performed using statistical tests to compare outcomes between the groups, including nihss (national institutes of health stroke scale), mrs (modified rankin scale), and bi (barthel index) scores. safety analysis will involve monitoring and categorizing adverse events (aes) and treatment-emergent adverse events (teaes) using standardized medical terminology. adverse events will be evaluated based on their relationship to the study drug, seriousness, severity, actions taken, and outcomes. clinical laboratory parameters, vital signs, and physical examinations will also be assessed.

Eligibility criteria:
inclusion criteria: * adult males or females aged 18 years through 78 years (have not had their 79th birthday) * patient or legally acceptable representative (lar) willing to give informed consent before study procedure. * stroke is ischemic in origin and radiologically confirmed computed tomography (ct) scan or diagnostic magnetic resonance imaging (mri) before enrolment. no hemorrhage as proved by cerebral ct/mri scan. * cerebral ischemic stroke patients presenting within 24 hours after onset of symptoms with mrs score of 3-4 (pre-stroke mrs score of 0 or 1) and nihss score \>5 (nihss level of consciousness (1a) score must be \< 2). this includes cerebral ischemic stroke patients who completely recovered from earlier episodes before having a new or fresh stroke. * the patient is \<24 hours from the time of stroke onset when the first dose of sovateltide therapy is administered. time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when the patient was last seen or was self-reported to be normal. * reasonable expectation of availability to receive the full sovateltide course of therapy and to be available for subsequent follow-up visits. exclusion criteria: * patients receiving endovascular therapy or is a candidate for any surgical intervention for the treatment of stroke, which may include but not limited to endovascular techniques. * patients classified as comatose are defined as a patient who requires repeated stimulation to attend or is obtunded and requires strong or painful stimulation to make movements (nihss level of consciousness (1a) score ≥ 2). * evidence of intracranial hemorrhage (intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, an acute or chronic subdural hematoma on the baseline ct or mri scan 4. known pregnancy. * confounding pre-existing neurological or psychiatric disease. * concurrent participation in any other therapeutic clinical trial. * evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol, impair the assessment of outcome, or in which sovateltide therapy would be contraindicated or might cause harm to the patient.

Keywords: stroke endothelin endothelin b receptors ischemia irl 1620 sovateltide neural progenitors